Biotron (BIT) Short Interest
Biotron (ASX:BIT) had 0.03% of shares reported as short positions as of 17 Nov 2025, representing 421,583 shares. Biotron operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Biotron
Biotron Limited is an Australian biotechnology company focused on developing and commercializing antiviral therapies. Their lead compound, BIT225, is in Phase 2 development for HIV-1 and Hepatitis C, targeting viroporin proteins crucial for viral pathogenicity. The company leverages a proprietary screening platform and has a library of compounds with potential against various viral diseases, including SARS-CoV-2.
Short position
Biotron (ASX:BIT) has 0.03% of its shares on issue reported as short positions as of 17 Nov 2025, or about 421,583 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.16% in February 2023. BIT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4BIT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Biotron
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss BIT
Start a research thread or post the first pulse update